Finance entity
Every one of those 1 sits in a single category, earnings. Pelthos Therapeutics Inc. is most often covered alongside Ameluz, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6.4 in the same window.
Last mentioned: Mar 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, earnings. Pelthos Therapeutics Inc. is most often covered alongside Ameluz, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6.4 in the same window. They are less corroborated than the beat average, carrying 2 original sources each against 2.7 for the same window. We currently track 1 Finance story that mention Pelthos Therapeutics Inc., all published on March 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 105 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Pelthos Therapeutics Inc.. Shared-story counts are live from our verified record — not editorial picks.
Armanino Foods and Biofrontera Inc. both reported record-breaking fourth-quarter and full-year 2025 financial results on March 19, 2026. These reports highlight strong execution in the specialty food and dermatological pharmaceutical sectors, respectively.
Pelthos Therapeutics Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
